United States securities and exchange commission logo





                           August 17, 2023

       Henry Gosebruch
       Chief Executive Officer
       Neumora Therapeutics, Inc.
       490 Arsenal Way, Suite 200
       Watertown, Massachusetts 02472

                                                        Re: Neumora
Therapeutics, Inc.
                                                            Amendment No. 9 to
Draft Registration Statement on Form S-1
                                                            Submitted August 9,
2023
                                                            CIK No. 0001885522

       Dear Henry Gosebruch:

              We have reviewed your amended draft registration statement and
have the following
       comment. In our comment we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comment applies to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to this
comment and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 9 to Draft Registration Statement on Form S-1 submitted
August 9, 2023

       Prospectus Summary
       Overview, page 1

   1.                                                   We note your statements
throughout the prospectus that several of your programs target
                                                        novel mechanisms of
actions that "have shown preclinical and clinical validation" by
                                                        Neumora and other
leading biopharmaceutical companies. Please revise your disclosure to
                                                        explain what you mean
by "validation" and provide support for each statement. Please
                                                        also ensure that this
disclosure does not imply that approval by the FDA or similar
                                                        regulatory bodies is
assured, as such determination is not within the control of the
                                                        company.
 Henry Gosebruch
Neumora Therapeutics, Inc.
August 17, 2023
Page 2

       You may contact Eric Atallah at 202-551-3663 or Al Pavot at 202-551-3738
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Daniel Crawford at 202-551-7767 or Laura Crotty at 202-551-7614 with any other
questions.



                                                         Sincerely,
FirstName LastNameHenry Gosebruch
                                                         Division of
Corporation Finance
Comapany NameNeumora Therapeutics, Inc.
                                                         Office of Life
Sciences
August 17, 2023 Page 2
cc:       Phillip Stoup, Esq.
FirstName LastName